Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ocugen, Inc.OCGN · Entity 5550 | Director | January 01, 2021 | January 04, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ocugen, Inc.
Report date January 01, 2021 · Filed January 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.83 · Expires 2031-01-01 | Direct | 126,000 |
Reported balance
After 2021-01-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-01 · Grant · Acquired 126,000 · Balance 126,000 F1: The option vests monthly in equal installments over three years commencing on February 1, 2021, subject to continued service with the Company on the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests monthly in equal installments over three years commencing on February 1, 2021, subject to continued service with the Company on the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2021 Filed Jan 4, 2021 22:47 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 126,000 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001192482-21-000023 · edgar.xml · derivative · entry 1 Taspolatoglu Suha · CIK 0001790351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,000 Underlying: Common Stock · 126,000 shares Expires 2031-01-01 F1 · derivative.exercise_date: The option vests monthly in equal installments over three years commencing on February 1, 2021, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| January 02, 2020 Filed Jan 4, 2020 01:37 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOptions (Right to Buy) · Derivative | 54,000 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001192482-20-000022 · edgar.xml · derivative · entry 1 Taspolatoglu Suha · CIK 0001790351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2030-01-02 F1 · derivative.exercise_date: The options vest monthly in equal installments over three years commencing on February 2, 2020, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.